Corvus Pharmaceuticals targets Q1 2027 futility analysis for PTCL and Q3 2027 topline data for AD trials of soquelitinib.
Corvus Pharmaceuticals outlined key clinical milestones for soquelitinib, its selective ITK inhibitor, including a futility analysis for peripheral T-cell lymphoma (PTCL) in Q1 2027. The company also expects topline data from its atopic dermatitis (AD) trials in Q3 2027, focusing on accelerating patient enrollment and trial execution.
Management emphasized soquelitinib as a priority during its Q2 2026 earnings call, directing resources toward advancing these programs. The drug’s first-in-class status and targeted mechanism position it as a potential catalyst for the company’s pipeline.
No immediate market reaction was disclosed, but the timeline updates provide clarity on near-term catalysts for CRVS shares.